California Public Employees Retirement System Concert Pharmaceuticals, Inc. Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$3.77 - $5.24 $220,545 - $306,540	-58,500 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$4.86 - $13.07 $26,598 - $71,532	-5,473 Reduced 8.56%	58,500 $292,000
Q4 2020 Feb 02, 2021	SELL	$9.48 - $12.84 $11,376 - $15,408	-1,200 Reduced 1.84%	63,973 $809,000
Q3 2020 Nov 05, 2020	BUY	$8.67 - $10.82 $15,606 - $19,476	1,800 Added 2.84%	65,173 $640,000
Q2 2020 Aug 12, 2020	SELL	$7.8 - $11.52 $96,064 - $141,880	-12,316 Reduced 16.27%	63,373 $631,000
Q1 2020 May 12, 2020	SELL	$5.98 - $13.09 $253,617 - $555,159	-42,411 Reduced 35.91%	75,689 $669,000
Q4 2019 Jan 27, 2020	SELL	$5.71 - $9.22 $207,844 - $335,608	-36,400 Reduced 23.56%	118,100 $1.09 Million
Q3 2019 Oct 31, 2019	BUY	$5.88 - $12.35 $49,980 - $104,975	8,500 Added 5.82%	154,500 $908,000
Q2 2019 Aug 15, 2019	SELL	$9.44 - $13.12 $29,065 - $40,396	-3,079 Reduced 2.07%	146,000 $1.75 Million
Q1 2019 May 03, 2019	BUY	$12.07 - $17.54 $721,786 - $1.05 Million	59,800 Added 66.98%	149,079 $1.8 Million
Q4 2018 Feb 08, 2019	BUY	$11.25 - $16.17 $54,000 - $77,616	4,800 Added 5.68%	89,279 $1.12 Million
Q3 2018 Nov 13, 2018	SELL	$12.82 - $17.88 $46,152 - $64,368	-3,600 Reduced 4.09%	84,479 $1.25 Million
Q2 2018 Aug 15, 2018	BUY	$16.83 - $21.66 $51,819 - $66,691	3,079 Added 3.62%	88,079 $1.48 Million
Q3 2017 Nov 15, 2017	BUY	$13.91 - $15.31 $1.18 Million - $1.3 Million	85,000	85,000 $1.25 Million

Others Institutions Holding CNCE

# of Institutions

Shares Held

Call Options Held

Put Options Held

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About CONCERT PHARMACEUTICALS, INC.

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

More about CNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account